Press Releases Year None2020201920182017 November 5, 2018 SpringWorks Therapeutics Receives FDA Orphan Drug Designation for MEK Inhibitor (PD-0325901) for the Treatment of Neurofibromatosis Type 1 PDF Version September 6, 2018 BeiGene and SpringWorks Therapeutics Enter into Global Clinical Collaboration to Evaluate Targeted Combination Therapy in Advanced Solid Tumors PDF Version September 5, 2018 SpringWorks Therapeutics Announces Appointment of Saqib Islam as Chief Executive Officer PDF Version March 5, 2018 SpringWorks Therapeutics to Present at Cowen and Company’s 38th Annual Health Care Conference PDF Version January 5, 2018 SpringWorks Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference PDF Version September 25, 2017 SpringWorks Therapeutics Launches with $103M in Series A Funding and Rights to Four Clinical Programs PDF Version Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4
November 5, 2018 SpringWorks Therapeutics Receives FDA Orphan Drug Designation for MEK Inhibitor (PD-0325901) for the Treatment of Neurofibromatosis Type 1 PDF Version
September 6, 2018 BeiGene and SpringWorks Therapeutics Enter into Global Clinical Collaboration to Evaluate Targeted Combination Therapy in Advanced Solid Tumors PDF Version
September 5, 2018 SpringWorks Therapeutics Announces Appointment of Saqib Islam as Chief Executive Officer PDF Version
March 5, 2018 SpringWorks Therapeutics to Present at Cowen and Company’s 38th Annual Health Care Conference PDF Version
January 5, 2018 SpringWorks Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference PDF Version
September 25, 2017 SpringWorks Therapeutics Launches with $103M in Series A Funding and Rights to Four Clinical Programs PDF Version
